aTYR PHARMA (ATYR) EBITDA (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly EBITDA came in at -$10.9 million in Q2 2026, up 46.43% on a YoY basis from -$7.4 million in Q2 2025, and up 4.85% quarter-over-quarter from -$11.4 million in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) EBITDA (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported EBITDA for 13 consecutive years, with -$10.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA rose 46.43% year-over-year to -$10.9 million; the trailing twelve-month figure through Jun 2026 stood at -$63.9 million (up 8.84% YoY), and the FY2025 full-year result was -$77.6 million, down 14.3% from the prior year.
- EBITDA climbed to -$10.9 million in Q2 2026 per ATYR's latest filing, from -$11.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$8.0 million in Q4 2022 and bottomed at -$26.7 million in Q3 2025.
- Historically, EBITDA has averaged -$15.0 million across 5 years, with a median of -$14.2 million in 2023.
- The sharpest annual moves came in 2023 and 2026: EBITDA sank 100.74% in 2023, then surged 46.43% in 2026.
- Over 5 years, EBITDA stood at -$8.0 million in 2022, then tumbled by 100.74% to -$16.0 million in 2023, then rose by 0.87% to -$15.8 million in 2024, then rose by 6.47% to -$14.8 million in 2025, then rose by 26.46% to -$10.9 million in 2026.
- According to Business Quant data, EBITDA over the past three periods registered -$10.9 million, -$11.4 million, and -$14.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | -815.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | 493.00 Mn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -365.99 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | -10.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -10.88 Mn |
| Mar 31, 2026 | -11.44 Mn |
| Dec 31, 2025 | -14.80 Mn |
| Sep 30, 2025 | -26.75 Mn |
| Jun 30, 2025 | -20.31 Mn |
| Mar 31, 2025 | -15.77 Mn |
| Dec 31, 2024 | -15.82 Mn |
| Sep 30, 2024 | -18.14 Mn |
| Jun 30, 2024 | -17.32 Mn |
| Mar 31, 2024 | -16.64 Mn |
| Dec 31, 2023 | -15.96 Mn |
| Sep 30, 2023 | -12.62 Mn |
| Jun 30, 2023 | -13.56 Mn |
| Mar 31, 2023 | -12.79 Mn |
| Dec 31, 2022 | -7.95 Mn |
| Sep 30, 2022 | -13.49 Mn |
| Jun 30, 2022 | -12.58 Mn |
| Mar 31, 2022 | -12.38 Mn |
| Dec 31, 2021 | -8.64 Mn |
| Sep 30, 2021 | -7.73 Mn |